Valerio Therapeutics completes acquisition of Etherna Immunotherapies
Bitget2026/10/12 06:19- Valerio Therapeutics completed the acquisition of Etherna Immunotherapies, taking 100% of its share capital and voting rights.
- Deal valued Etherna at an enterprise value of EUR 30 million, funded through cash consideration and share consideration.
- Cash portion was funded via issuance of 68,220,333 new ordinary shares at EUR 0.59 each, raising about EUR 40.25 million.
- Transaction expands an integrated RNA platform spanning nucleic acid chemistry, lipid nanoparticle delivery, targeted moiety engineering, manufacturing.
- Post-transaction share capital totals 587,615,993 shares, with Artal International holding 42.6%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Starbucks (SBUX.US) officially refutes rumors: clearly denies acquiring Chipotle (CMG.US), focuses on "Back to Starbucks" transformation strategy
Starbucks publicly clarified on Monday that the company has not acquired Chipotle Mexican Grill, putting an end to the previous acquisition rumors.
BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized
BlackRock has turned bullish on U.S. Treasury bonds for the first time in six years, upgrading short-term bonds to overweight and downgrading U.S. equities to neutral, stating that rate hike expectations are excessive and it is time to lock in yields.
AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review
Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).
4 Big Bank Earnings to Watch This Week as Wall Street Turns Bullish
Crypto prices
More
